These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9292)

  • 21. Placebo-controlled, double-blind clinical trial of alprenolol in African hypertensive patients.
    Salako LA; Falase AO; Aderounmu AF
    Curr Med Res Opin; 1979; 6(5):358-63. PubMed ID: 396111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prazosin first dose phenomenon during combined treatment with a beta-adrenoceptor blocker in hypertensive patients.
    Seideman P; Grahnén A; Haglund K; Lindström B; Von Bahr C
    Br J Clin Pharmacol; 1982 Jun; 13(6):865-70. PubMed ID: 7093116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of sympathetic cardiovascular reflexes and urinary catecholamines when selecting patients for antihypertensive treatment with beta-adrenergic blocking drugs.
    Iisalo E; Lehtonen A
    Ann Clin Res; 1975 Apr; 7(2):71-5. PubMed ID: 1103708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic interference of alprenolol with dihydralazine in normal and hypertensive man.
    Sannerstedt R; Stenberg J; Johnsson G; Werkö L
    Am J Cardiol; 1971 Sep; 28(3):316-20. PubMed ID: 5155758
    [No Abstract]   [Full Text] [Related]  

  • 25. Combined pharmacokinetic and pharmacodynamic studies on alprenolol and 4-hydroxy-alprenolol in man.
    Ablad B; Borg KO; Johnsson G; Regårdh CG; Sölvell L
    Life Sci; 1974 Feb; 14(4):693-704. PubMed ID: 4823626
    [No Abstract]   [Full Text] [Related]  

  • 26. Metabolic changes in muscle on long-term alprenolol therapy.
    Frisk-Holmberg M; Jorfeldt L; Juhlin-Dannfelt A; Karlsson J
    Clin Pharmacol Ther; 1979 Nov; 26(5):566-71. PubMed ID: 498698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of cardiodepressant potency of nadolol, alprenolol, propranolol and pindolol, beta-blocking agents, in heart-lung preparation and blood-perfused excised papillary muscle preparation of the dog.
    Ono H; Kanazawa Y; O'Hara N; Hashimoto K
    Jpn J Pharmacol; 1984 Dec; 36(4):507-17. PubMed ID: 6151997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study of beta andreoceptor antagonists on the isolated atria of control and of the reserpine treated rabbits.
    Hague MA; Darabi MK; Khalighi MR
    Pahlavi Med J; 1977 Jul; 8(3):326-44. PubMed ID: 21372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and biopharmaceutics of some adrenergic beta-receptor antagonists with special emphasis on alprenolol and metoprolol.
    Regårdh CG
    Acta Pharmacol Toxicol (Copenh); 1975; 37(1):1-39. PubMed ID: 237402
    [No Abstract]   [Full Text] [Related]  

  • 30. A dose ranging study of atenolol in hypertension: fall in blood pressure and plasma renin activity, beta-blockade and steady-state pharmacokinetics.
    Ishizaki T; Oyama Y; Suganuma T; Sasaki T; Nakaya H; Shibuya T; Sato T
    Br J Clin Pharmacol; 1983 Jul; 16(1):17-25. PubMed ID: 6349668
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Beta adrenergic drugs in arterial hypertension].
    Gysling E
    Union Med Can; 1972 Jul; 101(7):1336-41. PubMed ID: 4402882
    [No Abstract]   [Full Text] [Related]  

  • 32. Double-blind comparison of metoprolol, alprenolol, and oxprenolol in hypertension.
    Tuomilehto J; Nissinen A
    Eur J Clin Pharmacol; 1979; 16(6):369-74. PubMed ID: 393518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics, beta-adrenoceptor blockade and anti-hypertensive action of labetalol during chronic oral treatment.
    Sanders GL; Davies DM; Rawlins MD
    Br J Clin Pharmacol; 1980 Aug; 10(2):121-6. PubMed ID: 6252915
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of catecholamine infusions on myocardial blood flow, metabolic heat production and on general haemodynamics, before and after alprenolol (H56-28), in anaesthetized cats.
    Parratt JR; Wadsworth RM
    Br J Pharmacol; 1970 May; 38(3):554-71. PubMed ID: 4392541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haemodynamic effects of saluretic treatment and beta-receptor blockade in patients with essential hypertension.
    Bevegård S; Castenfors J; Danielson M
    Acta Med Scand; 1977 Jan; 201(1-2):99-104. PubMed ID: 835380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "Low T3-syndrome" in acute myocardial infarction--relationship to beta-adrenergic blockade and clinical course.
    Pedersen F; Perrild H; Rasmussen SL; Skovsted L
    Eur J Clin Pharmacol; 1984; 26(6):669-73. PubMed ID: 6149125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship of propranolol pharmacokinetics to antihypertensive effect and beta-adrenergic blockade in the treatment of hypertension.
    Krediet RT; Dunning AJ; Offerhaus L
    Eur J Clin Pharmacol; 1980 Nov; 18(5):391-4. PubMed ID: 6108222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activity and duration of action of pindolol and alprenolol compared in healthy volunteers.
    Aellig WH
    Eur J Clin Pharmacol; 1978 Dec; 14(5):305-8. PubMed ID: 729623
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A within-patient comparison of alprenolol and propranolol in hypertension.
    Berglund G; Hansson L
    Acta Med Scand; 1973 Jun; 193(6):547-50. PubMed ID: 4721964
    [No Abstract]   [Full Text] [Related]  

  • 40. Haemodynamic consequences of intrinsic sympathomimetic activity in relation to changes in plasma renin activity and noradrenaline during beta-blocker therapy for hypertension.
    Man in't Veld AJ; Schalekamp MA
    Postgrad Med J; 1983; 59 Suppl 3(689):140-58. PubMed ID: 6139800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.